Wall st style report cites 683% to 1857% gain

Here we go.

Successful completion Phase 1 as of today Tick

Fully funded for phase 2

All on time and on budget

From the research report published on the ACW website today. Link pasted here. http://actinogen.com.au/initiation-of-coverage.pdf

Our target price of $0.35 sits in the low point of our valuation range.

Wall St in 2015 has had several multi-billion dollar re-ratings in the Alzheimer’s space. Given the
reinvigorated interest towards Alzheimer’s, we believe this is the best time for small cap biotechs
focused on Alzheimer’s therapies to attract institutional interest and significant premium in valuation(s)

Data from Biogen’s Phase 1b PRIME Study Added $40B US to Biogen’s Market Cap